Skip to content

Cluster randomised trial of low molecular weight heparins - Directly through Epic

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502402-32-00
Enrollment
65000
Registered
2023-01-18
Start date
Unknown
Completion date
2025-03-25
Last updated
2024-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism

Brief summary

Major bleeding requiring blood transfusion and all-cause mortality at 30 days

Detailed description

1. All-cause 30 day mortality 2. All-cause 365 day mortality 3. Blood transfusion during admission 4. Pulmonary embolism at 30 days 5. Heparin induced thrombocytopenia 6. Liver failure 7. Length of hospital admission 8. Days alive out of hospital

Interventions

DRUGTINZAPARIN
DRUGDALTEPARIN

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Major bleeding requiring blood transfusion and all-cause mortality at 30 days

Secondary

MeasureTime frame
1. All-cause 30 day mortality 2. All-cause 365 day mortality 3. Blood transfusion during admission 4. Pulmonary embolism at 30 days 5. Heparin induced thrombocytopenia 6. Liver failure 7. Length of hospital admission 8. Days alive out of hospital

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026